Purpose Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors
comprising various breast cancers simply defined by the absence of estrogen receptor …

A proliferative marker, expressed as the percentage of cells in a cell cycle, has been
developed and used as a discriminant of more aggressive malignant phenotypes in early …

Chemotherapy is the primary established systemic treatment for patients with triple-negative
breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of …

Triple‐negative breast cancer, characterized by tumors that do not express estrogen
receptor (ER), progesterone receptor (PR), or HER‐2 genes, represents an important clinical …

Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen
and progesterone receptor as well as human epidermal growth factor receptor 2. It is …

Cytotoxic chemotherapy remains the mainstay of treatment for triple-negative breast cancer
(TNBC) despite the promise of new targeted and biologic agents. Many studies have shown …

Background Triple-negative breast cancer (TNBC) lacking expression of steroid receptors
and human epidermal growth factor receptor 2, having chemotherapy as the only …

Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little
therapeutic progress during the past several decades and still the standard of care remains …

With advances in genetic studies, breast cancer has been identified as a heterogeneous
disease with distinct subtypes that respond variably to different therapies. The concept of …

Patients with triple‐negative breast cancer (TNBC) have the worst clinical outcomes when
compared to other subtypes of breast cancer. Nanotechnology‐assisted photothermal …